PRPH
ProPhase Labs, Inc.0.1150
+0.0019+1.68%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.31MP/E (TTM)
-Basic EPS (TTM)
-1.98Dividend Yield
0%Recent Filings
8-K
Launches BE-Smart™ sale process
ProPhase Labs kicked off a sale or strategic partnership process for its ready-to-commercialize BE-Smart™ esophageal cancer test on February 3, 2026, targeting over 70 potential acquirers. It also updated that over 60% of legacy COVID-19 receivables from bankrupt lab subs are from commercial payors with higher recovery rates. Process just launched.
8-K
Crown collections update issued
ProPhase Labs issued an operational update on January 26, 2026, detailing progress in its Crown Medical Collections initiative for legacy COVID-19 testing receivables from lab subsidiaries in Chapter 11. The filing furnishes the press release as Exhibit 1.1. Collections advance amid bankruptcy proceedings.
8-K
Secures $10M equity line
IPO
Website
Employees
Sector
Industry
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BNR
Burning Rock Biotech Limited
18.74+2.98
DGX
Quest Diagnostics Incorporated
178.66-5.45
IDXG
Interpace Biosciences, Inc.
1.14-0.02
LH
Labcorp Holdings Inc.
258.11-5.22
MDXH
MDxHealth SA
3.36+0.05
MEHCQ
CHROME HLDG CO
3.50+0.00
OPK
Opko Health, Inc.
1.31-0.04
PRE
Prenetics Global Limited
16.58+1.95
PSNL
Personalis, Inc.
7.98-0.50